The hypothalamic neuropeptide melanin-concentrating hormone (MCH) increases feeding when injected intracerebroventricularly in rats. To identify the hypothalamic nuclei responsible for the orexigenic effect, we injected the peptide into discrete hypothalamic nuclei known to express the MCH receptor, MCH1R. MCH (0.6 nmol) elicited a rapid and significant increase in feeding in satiated rats following injection into the arcuate nucleus (0 -1 h: 421 ؎ 60%; P < 0.01). An elevation in feeding was also observed following injection into the paraventricular nucleus, which was sustained up to 4 h post injection (0 -4 h: 218 ؎ 29%; P < 0.01). A significant increase in feeding during this time period was also observed following injection into the dorsomedial nucleus (0 -4 h: 155 ؎ 12%; P < 0.05). No significant alteration in feeding was observed following injection into the supraoptic nucleus, lateral hypothalamic area, medial preoptic area, anterior hypothalamic area, or ventromedial nucleus of the hypothalamus. To identify the neurotransmitters that may be potentially involved in this effect, we examined their release from hypothalamic explants in vitro following exogenous MCH administration. MCH ( 
M ELANIN-CONCENTRATING HORMONE (MCH)
has been implicated in the control of appetite and body weight regulation and is widely targeted as a possible avenue for treatment of obesity. Hypothalamic MCH mRNA and peptide levels are increased in genetically obese Lep ob / Lep ob mice compared with nonobese wild-type controls (1) . In addition, fasting further increases the expression of MCH mRNA in both normal and obese animals (1) . Intracerebroventricular (ICV) administration of MCH increases food intake in rats (1, 2) and, when administered chronically in rodents, results in weight gain and enhanced susceptibility to diet-induced obesity (3, 4) . Targeted deletion of the MCH gene in mice reduces food intake and body weight (5) . MCH Ϫ/Ϫ mice also have an inappropriately elevated metabolic rate that may contribute to the reduction in body weight. Chronic overexpression of the MCH gene in mice results in obesity and insulin resistance (6) . MCH therefore seems to be an important regulator of feeding and energy balance.
Within the hypothalamus, MCH expression is localized to perikarya in the lateral hypothalamic (LHA) and zona incerta regions (7) . Immunohistochemical studies in the rat have shown widespread neuronal projections throughout the brain (8) . MCH immunoreactive boutons are observed in particular areas of the hypothalamus implicated in feeding and body weight regulation (8) .
Two MCH receptors, MCH1R and MCH2R, have recently been identified (9 -18) . However, it has been shown that rodents only express functional MCH1R (19) . MCH1R (or SLC-1) mRNA and immunoreactivity are found throughout the brain, with particularly high levels in the hypothalamus, in areas implicated in feeding regulation (20) . Targeted deletion of the MCH1R gene resulted in mice that are hyperphagic and lean (21, 22) . This is likely to be a consequence of the elevated metabolism and locomotor activity observed in these animals. MCH1R
Ϫ/Ϫ mice are resistant to diet induced obesity, with no alteration in body weight following chronic administration of MCH or a high-fat diet (21, 22) . Further confirmation of the role of MCH1R in the mediation of MCH on feeding has been provided by recent studies using the selective high affinity MCH1R antagonist SNAP-7941 (23) . Systemic administration of the antagonist inhibited the increase in food intake elicited by ICV MCH. In addition, chronic administration of the compound to rats with dietinduced obesity resulted in a marked reduction in body weight. These findings suggest MCH1R plays a physiological role in energy homeostasis.
To characterize the areas of the hypothalamus in which MCH influences feeding, MCH was injected into discrete hypothalamic nuclei known to both exhibit MCH1R immuAbbreviations: aCSF, Artificial cerebrospinal fluid; AgRP, agoutirelated peptide; AHA, anterior hypothalamic area; ARC, arcuate nucleus; CART, cocaine-and amphetamine-regulated transcript; DMN, dorsomedial nucleus; ICV, intracerebroventricular; LHA, lateral hypothalamic area; MCH, melanin-concentrating hormone; MCH1R and MCH2R, MCH receptors; MPO, medial preoptic area; NMU, neuromedin U; NPY, neuropeptide Y; POMC, proopiomelanocortin; PVN, paraventricular nucleus; SON, supraoptic nucleus; VMN, ventromedial nucleus.
noreactivity (20) and to have previously been implicated in feeding regulation, and food intake monitored. To investigate the mechanism by which MCH increases feeding, the effect of MCH on the release of other hypothalamic appetiteregulating neuropeptides in vitro from hypothalamic explants was examined. 
Materials and Methods

Intranuclear cannulation
Animal surgical procedures and handling were carried out as previously described (24 (25) . Animals were allowed a 7-d rest period before the onset of studies. All compounds were dissolved in 0.9% saline and administered, in the early light phase, as previously described (24, 26 -28) . The study was of a random cross over design, in which half of the animals in each group received 0.6 nmol MCH and the remainder received saline (n ϭ 9 -13/ nucleus). The dose of MCH administered was based on previously published (2, 29) and pilot in vivo studies, and represented a halfmaximal point on the dose-response curve. After a 4-d washout period, animals that had previously received MCH then received saline and vice versa. Following injection, animals were returned to their home cages containing a preweighed amount of chow. At 1, 2, 4, 8, and 24 h post injection, food remaining in the cage dispenser was weighed using an ATP Instrumentation GW 600 balance (ATP Instrumentations, Ltd., Ashby-De-la-Zouche, Leicestershire, UK) recording to the nearest 0.1 g.
Correct cannula placement was confirmed histologically at the end of the study period. Following injection of black ink, animals were decapitated, the guide cannulae removed, and the brains immediately frozen in liquid nitrogen and stored at Ϫ70 C. Brains were sliced on a cryostat (Bright Instruments, Huntingdon, Cambridgeshire, UK) into 15 m coronal sections and stained with cresyl violet. Sections were compared with the corresponding section from the rat brain atlas (25) . The ink remained localized at the injection site at the guide tip without significant diffusion. Data from an animal was excluded if its injection site extended more than 0.2 mm outside the intended hypothalamic injection site or if any ink was detected in the cerebral ventricular system. The final numbers of animals with correct cannula placement and therefore included in the data analysis for each nucleus were: MPO (n ϭ 12), SON (n ϭ 13), AHA (n ϭ 13), PVN (n ϭ 13), VMN (n ϭ 12), DMN (n ϭ 13), ARC (n ϭ 9), and LHA (n ϭ 13).
This intranuclear injection method has previously been used to localize the hypothalamic feeding effects of ␣-MSH, AgRP (83-132) (agouti-related peptide), ghrelin, CART (55-102) (cocaine-and amphetamine-regulated transcript), and neuromedin U (NMU) (Refs. 24, 26 and 28).
Static incubation of hypothalamic explants
The static incubation system used was a modification of the method previously described (31) . Male Wistar rats (n ϭ 17-34) were killed by decapitation and the whole brain immediately removed. The brain was mounted with ventral surface uppermost and placed in a vibrating microtome (Microfield Scientific Ltd., Dartmouth, UK). A 1.7-mm slice was taken from the basal hypothalamus and incubated in individual tubes containing 1 ml of artificial cerebrospinal fluid (aCSF) (20 mm NaHCO 3 , 126 mm NaCl, 0.09 mm Na 2 HPO 4 , 6 mm KCl, 1.4 mm CaCl 2 , 0.09 mm MgSO 4 , 5 mm glucose, 0.18 mg/ml ascorbic acid, and 100 g/ml aprotinin), equilibrated with 95% O 2 and 5% CO 2 . The hypothalamic explant includes all of the nuclei injected in the in vivo studies. The tubes were placed on a shaking platform in a water bath maintained at 37 C. After an initial 2-h equilibration period, the hypothalamic explants were incubated for 45 min in 600 l aCSF (basal period) before being challenged with 1 m MCH in 600 l aCSF. Finally, the viability of the tissue was verified by a 45-min exposure to aCSF containing 56 mm KCl; isotonicity was maintained by substituting K ϩ for Na ϩ . At the end of each period, the aCSF was removed and frozen at Ϫ20 C pending measurement of neuropeptide Y (NPY), AgRP, ␣-MSH, CART, and orexin A by RIA.
RIAs
NPY, AgRP, ␣-MSH, CART, and orexin A levels were measured using in house RIAs (26, (32) (33) (34) (35) .
Statistical analysis
Food intake data are expressed as mean Ϯ sem % control. One-way ANOVA with post hoc bonferonni analysis was used for multiple comparisons of food intake of MCH and saline-treated groups at each nucleus and time point. Peptide release from hypothalamic explants is expressed as fmol release/explant. Paired Student's t test was for comparison of peptide release from hypothalamic explants in basal, MCH, and potassium-stimulated periods. Values of P Ͻ 0.05 were considered significant.
Results
Effect of intranuclear administration of MCH on food intake
The data below are expressed as mean Ϯ sem % saline control. Mean food intake for saline-injected controls at each time point for all nuclei were: 0 -1 h, 0.8 Ϯ 0.1 g; 1-2 h, 0.4 Ϯ 0.1 g; 2-4 h, 0.6 Ϯ 0.1 g; 4 -8 h, 2.0 Ϯ 0.2 g; and 8 -24 h, 18.9 Ϯ 0.5 g. Injection of MCH into the ARC induced a dramatic 4-fold increase in feeding at 0 -1 h post injection (421 Ϯ 60% control; P Ͻ 0.01) (Fig. 1G) . Food intake levels were indistinguishable from control levels from 2 h post injection. Administration of 0.6 nmol MCH caused a sustained elevation in feeding following administration into the PVN, although this failed to reach significance at any individual time point (0 -1 h, 183 Ϯ 25% control; 1-2 h, 214 Ϯ 44% control; 2-4 h, Cannulae were cut to 1 mm above the depth of the nuclei. 284 Ϯ 78%, P ϭ not significant) (Fig. 1D) . Analysis of cumulative food intake data found total 4 h food intake to be significantly elevated from saline-injected control levels (218 Ϯ 29% control; P Ͻ 0.01) (Fig. 2) . This elevation was comparable to the 4-h cumulative food intake following MCH administration into the ARC (198 Ϯ 26% control; P Ͻ 0.01 vs. saline control) (Fig. 2) . In addition, 0.6 nmol MCH administered into the DMN significantly increased feeding during this 4-h period post injection (155 Ϯ 12% control; P Ͻ 0.05) (Fig. 2) . A trend toward increased feeding was observed following MCH administration into the SON (0 -1 h, 216 Ϯ 51% control) and AHA (0 -1 h, 170 Ϯ 36% control), although this failed to reach significance (Fig. 1, B and C) . There was no significant alteration in feeding following administration of MCH into the MPO, VMN, or LHA at any time point measured (Fig. 1, A, E , and H).
Effect of MCH on peptide release from hypothalamic explants
MCH (100 nm) significantly stimulated the release of NPY (37.8 Ϯ 6.0 fmol/explant vs. basal 30.2 Ϯ 4.3 fmol/explant, P Ͻ 0.05) and AgRP (4.1 Ϯ 0.6 fmol/explant vs. basal 2.4 Ϯ 0.2 fmol/explant, P Ͻ 0.05) from medial basal hypothalamic explants in vitro (Fig. 3, A and B) . MCH significantly attenuated the release of CART (112.3 Ϯ 12.4 fmol/explant vs. basal 167.4 Ϯ 13.0 fmol/explant, P Ͻ 0.001) and ␣-MSH (41.7 Ϯ 6.8 fmol/explant vs. basal 65.9 Ϯ 11.0 fmol/explant, P Ͻ 0.01) from hypothalamic explants (Fig. 3, C and D) . There was no effect of MCH on orexin A release from these explants (46.2 Ϯ 4.5 fmol/explant vs. basal 50.6 Ϯ 4.4 fmol/explant) (Fig. 3E) .
Discussion
We have shown that injection of MCH into the ARC, PVN, and DMN of the hypothalamus significantly increased feeding compared with saline-injected control levels. The greatest orexigenic response to MCH was observed following administration into the ARC where MCH induced a 4-fold increase in food intake compared with saline-injected control levels in the first hour post injection. Lesioning studies have implicated the ARC in the regulation of food intake and body weight (36) . Ablation of the ARC following neonatal monosodium glutamate treatment results in hyperphagia and obesity in rodents (37) . The ARC serves as an integrator of peripheral signaling and hypothalamic circuitry. The gut hormones ghrelin and peptide YY (3-36) both alter food intake and body weight following direct administration into the ARC (27, 38) . In addition, the hypothalamic neuropeptides ␣-MSH, CART, and NMU also alter feeding following injection into this nucleus (24, 26, 28) .
The ARC contains a number of neuropeptides known to influence feeding and body weight regulation. NPY and AgRP are coexpressed in neuronal cell bodies in the ARC and both are up-regulated with fasting (39, 40) . ICV administration of NPY or AgRP significantly increases food intake (41, 42) . Proopiomelanocortin (POMC), the precursor of the neuropeptide ␣-MSH, and CART are also colocalized in a subset of ARC neurons distinct from those that contain NPY and AgRP. ARC POMC and CART mRNA levels decrease with fasting (43, 44) . CART is also coexpressed with MCH in the LHA (45) . ICV administration of ␣-MSH reduces food intake in rodents (46) . ICV administration of CART (55-102), the putative active fragment, decreases feeding in rodents (43) but is associated with adverse behaviors thought to impair the ability to feed (24) . Recent studies have found intranuclear injection of CART (55-102) to increase feeding following administration into several hypothalamic nuclei, including the ARC (24) . It has been shown that these ARC neuropeptides are highly regulated by leptin. Kokkotou et al. demonstrated that MCH1R is also regulated by leptin, with expression levels in the ARC of Lep ob / Lep ob mice being 5-fold higher than their wild-type counterparts (47) . We found MCH to stimulate the release of NPY and AgRP and inhibit the release of ␣-MSH and CART from hypothalamic explants in vitro. It is possible that the large orexigenic response following administration of MCH into the ARC may be mediated, at least in part, via a modulation of these ARC neuropeptide feeding circuits. MCH may increase feeding by activating the orexigenic NPY/AgRP neurons, while concurrently inactivating anorectic POMC/CART neurons. In agreement, recent studies have shown activation of ARC neurons by MCH in hyperphagic rats (48) . Our data suggest that the LHA may have an influential effect on the regulation of appetite and body weight mediated by the ARC through MCH signaling mechanisms.
The PVN also plays an important role in feeding regulation. Virtually all known orexigenic and anorectic neuropeptides alter food intake following direct injection into the PVN (24, 26, 28, 49, 50) . Although initially not as big as that induced following administration into the ARC, the orexigenic effect following administration into the PVN was sustained up to 4 h post injection. Food intake remained elevated to approximately 300% of control levels during the 2-4 h postinjection period, with 4-h cumulative food intake indistinguishable from that of the ARC administered rats. Because many of the cell bodies of appetite regulating neurones present in the ARC project to the PVN, it may be postulated that this sustained orexigenic effect following MCH admin- istration may be through an action on the terminals of the same neurones projecting to the PVN.
Lesioning studies have implicated the DMN in the control of appetite and body weight (51) . AgRP (83-132), CART (55-102) and galanin increase feeding when directly injected into this nucleus (24, 26, 50) . Here we have found administration of MCH into the DMN also increases food intake. MCH stimulated the release of NPY from hypothalamic explants in vitro. It is possible, therefore, that the NPY system in the DMN plays a role in the effect of MCH on feeding. Further mechanistic studies are required to elucidate these pathways.
Although not significant, there was a trend toward an increase in feeding in the first hour post injection of MCH into the SON. The SON is not classically regarded as a center for feeding, however we have recently shown that CART (55-102) significantly increases feeding when administered here (24) . In addition, it has been reported that injection of the dopamine D2 receptor antagonist, sulpiride, into the SON significantly increased the food intake of anorectic tumor-bearing rats (52) . A similar trend was observed in the first hour post injection of MCH into the AHA. Several other neuropeptides including ␣-MSH, AgRP (83-132), and CART (55-102) have been shown to alter food intake when administered into the AHA (24, 26) .
MCH and the neuropeptide orexin A are localized to distinct cell bodies within the LHA. This area also contains MCH1R immunoreactivity (20) , though the cell types expressing MCH1R have not been identified. MCH may feedback to regulate its own release, or may influence orexin A release. However, exogenous administration of MCH to hypothalamic explants did not alter orexin A release compared with basal levels. In addition, we did not observe any alteration in feeding following administration into the LHA.
No alteration in feeding was observed following administration of MCH into the MPO or VMN of the hypothalamus. Both the VMN and MPO contain moderate to extensive MCH1R immunoreactivity (20) . The function of MCH1R in these areas remains unclear. It is possible that they mediate other actions of MCH such as regulation of sexual behavior or hormonal control (53) .
Although low doses of peptide were administered in the intranuclear studies, the possibility of diffusion of peptide from one site to another must always be considered. However, no alteration in feeding was observed following administration of MCH into the VMN, which is anatomically closer to the responsive ARC than the DMN and PVN. In addition, if the feeding response elicited was due to diffusion of peptide then a delayed orexigenic response might be expected. Our data imply a rapid onset increase in feeding evident from the earliest time point measured. We therefore conclude that, for the doses chosen in this study, the diffusion effect from one nucleus to another is small. This method of intranuclear administration has previously been used to map the hypothalamic feeding effects of numerous peptides including NPY, ␣-MSH, AgRP (83-132), galanin, ghrelin, CART (55-102), and NMU (Refs. 24, 26 -28, 49, and 50) .
In conclusion, we have shown MCH increases feeding following administration into the ARC, PVN, and DMN of the hypothalamus of rats. The most prominent orexigenic effects are observed following administration into the ARC and PVN. These effects may be mediated via activation or inhibition of neuronal feeding circuits projecting from the ARC to the PVN because MCH increases the release of the orexigenic NPY and AgRP and decreases the release of ␣-MSH and CART from hypothalamic explants. Further investigation of the role of MCH in the hypothalamic feeding circuitry may provide insight into potential routes of therapeutic intervention for human obesity.
